Download PDF
CC BY-NC-ND 4.0 · Nuklearmedizin
DOI: 10.1055/a-2353-5819
Review

Die moderne TARE 2023 – von der Palliativversorgung zur kurativen Behandlungsalternative

Modern TARE 2023 – from palliative care to a curative treatment alternative
Bernhard Gebauer
1   Radiology, Charité Universitätsmedizin Berlin, Berlin, Germany (Ringgold ID: RIN14903)
,
Federico Collettini
1   Radiology, Charité Universitätsmedizin Berlin, Berlin, Germany (Ringgold ID: RIN14903)
2   Berlin Institute of Health at Charite, Berlin, Germany (Ringgold ID: RIN522475)
,
Christian Helmut Pfob
3   Nuklearmedizin, Universitätsklinikum Augsburg, Augsburg, Germany (Ringgold ID: RIN39694)
,
Constantin Lapa
3   Nuklearmedizin, Universitätsklinikum Augsburg, Augsburg, Germany (Ringgold ID: RIN39694)
› Author AffiliationsSupported by: LinkCare GmbH
Supported by: SIRTEX Medical Europe GmbH
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Die selektive interne Radiotherapie (SIRT) oder transarterielle Radioembolisation (TARE) ist eine Behandlungsalternative beim hepatozellulären Karzinom (HCC) oder hepatisch metastasierten kolorektalen Karzinom (mCRC) und ist mittlerweile in vielen Leitlinien verankert. Der Artikel fasst die aktuellen Leitlinien zur SIRT/TARE beim HCC bzw. mCRC zusammen.

Abstract

Selective internal radiotherapy (SIRT) or transarterial radioembolisation (TARE) is an alternative treatment for hepatocellular carcinoma (HCC) or hepatic metastatic colorectal carcinoma (mCRC) and is now anchored in many guidelines. The article summarises the current guidelines on SIRT/TARE in HCC and mCRC.

Keywords

TARE - HCC - mCRC


Publication History

Received: 05 December 2023

Accepted after revision: 13 May 2024

Article published online:
16 July 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Referenzen

  • 1 Teichgräber U, Gebauer B. Correction: Radioembolisation mit Yttrium-90-Mikrosphären. Der Onkologe 2017; 23 (11) 951-60
    CrossrefGoogle Scholar
  • 2 Miller FH, Lopes Vendrami C, Gabr A. et al. Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review. Radiographics 2021; 41 (06) 1802-1818
    CrossrefPubMedGoogle Scholar
  • 3 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DKA). Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome Langversion 3.0, 2022, AWMF-Registernummer: 032/053OL [Internet]. [zitiert 3. Januar 2024]. https://www.leitlinienprogramm-onkologie.de/leitlinien/hcc-und-biliaere-karzinome/
    Google Scholar
  • 4 Reig M, Forner A, Rimola J. et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022; 76 (03) 681-693 DOI: 10.1016/j.jhep.2021.11.018. (PMID: 34801630)
    CrossrefPubMedGoogle Scholar
  • 5 Mikell JK, Dewaraja YK, Owen D. Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models. Semin Radiat Oncol 2020; 30 (01) 68-76 DOI: 10.1016/j.semradonc.2019.08.005. (PMID: 31727302)
    CrossrefPubMedGoogle Scholar
  • 6 Jeyarajah DR, Doyle MBM, Espat NJ. et al. Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm. J Gastrointest Oncol 2020; 11 (02) 443-460 DOI: 10.21037/jgo.2020.01.09. (PMID: 32399284)
    CrossrefPubMedGoogle Scholar
  • 7 DʼAbadie P, Walrand S, Lhommel R. et al. Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria. Curr Oncol 2022; 29 (04) 2422-2434
    CrossrefPubMedGoogle Scholar
  • 8 Galle PR, Forner A, Llovet JM. et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69 (01) 182-236
    CrossrefPubMedGoogle Scholar
  • 9 Van Cutsem E, Cervantes A, Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology 2016; 27 (08) 1386-1422
    CrossrefPubMedGoogle Scholar
  • 10 National Comprehensive Cancer Network. NCCN Guideline on Colon Cancer, Version 4.2023 [Internet]. [zitiert 3. Januar 2024]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428
    Google Scholar
  • 11 Singal AG, Llovet JM, Yarchoan M. et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023; 78 (06) 1922-1965
    CrossrefPubMedGoogle Scholar
  • 12 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DKA). S3-Leitlinie Kolorektales Karzinom, Langversion 2.1, 2019, AWMF Registrierungsnummer: 021/007OL [Internet]. [zitiert 3. Januar 2024]. http://www.leitlinienprogrammonkologie.de/leitlinien/kolorektales-karzinom/
    Google Scholar
  • 13 Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med 2010; 40 (02) 105-121 DOI: 10.1053/j.semnuclmed.2009.11.001. (PMID: 20113679)
    CrossrefPubMedGoogle Scholar
  • 14 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DKA). Diagnostik und Therapie des hepatozellulären Karzinoms, Langversion 1.0, 2013, AWMF Registrierungsnummer: 032–053OL [Internet]. [zitiert 3. Januar 2024]. http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html
    Google Scholar
  • 15 Salem R, Johnson GE, Kim E. et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology 2021; 74 (05) 2342-2352 DOI: 10.1002/hep.31819. (PMID: 33739462)
    CrossrefPubMedGoogle Scholar
  • 16 Chapman WC, Garcia-Aroz S, Vachharajani N. et al. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions. J Am Coll Surg 2017; 224 (04) 610-621
    CrossrefPubMedGoogle Scholar
  • 17 Salem R, Gordon AC, Mouli S. et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology 2016; 151 (06) 1155-1163.e2
    CrossrefPubMedGoogle Scholar
  • 18 Ettorre GM, Levi Sandri GB, Laurenzi A. et al. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World J Surg 2017; 41 (01) 241-249
    CrossrefPubMedGoogle Scholar
  • 19 Garin E, Tselikas L, Guiu B. et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6 (01) 17-29
    CrossrefPubMedGoogle Scholar
  • 20 Hermann AL, Dieudonné A, Ronot M. et al. Relationship of tumor radiation–absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH study. Radiology 2020; 296 (03) 673-684
    CrossrefPubMedGoogle Scholar
  • 21 Gardini AC, Tamburini E, Iñarrairaegui M. et al. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis of randomized trials. Onco Targets Ther 2018; 11: 7315-7321
    CrossrefPubMedGoogle Scholar
  • 22 Ludwig JM, Zhang D, Xing M. et al. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma. ur Radiol 2017; 27 (05) 2031-2041
    Google Scholar
  • 23 Abdel-Rahman OM, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2016 Feb 16;2. Update in: Cochrane Database Syst Rev. 2020 Jan 24;1.
    Google Scholar
  • 24 Gibbs P, Heinemann V, Sharma N. et al. Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. Clin Colorectal Cancer 2018; 17 (04) e617-e629
    CrossrefPubMedGoogle Scholar
  • 25 Mulcahy MF, Mahvash A, Pracht M. et al. Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. J Clin Oncol 2021; 39 (35) 3897-3907
    CrossrefPubMedGoogle Scholar
  • 26 Garlipp B, Gibbs P, van Hazel GA. et al. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial. Br J Surg 2019; 106 (13) 1837-1846 DOI: 10.1002/bjs.11283. (PMID: 31424576)
    CrossrefPubMedGoogle Scholar
  • 27 Llovet JM, Ducreux M, Lencioni R. et al. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. Erratum in: J Hepatol. 2012 Jun;56(6):1430. J Hepatol 2012; 56 (04) 908-943
    CrossrefPubMedGoogle Scholar
  • 28 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DKA, ). Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karziome, Langversion 2.0, 2021, AWMF Registernummer: 032/053OL [Internet]. [zitiert 3. Januar 2024]. Verfügbar unter. https://www.leitlinienprogramm-onkologie.de/leitlinien/hcc-und-billiäre-karzinome
    Google Scholar
  • 29 Yang J, Wang J, Zhou H. et al. Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: A randomized trial. Endoscopy 2018; 50 (08) 751-760 DOI: 10.1055/s-0043-124870. (PMID: 29342492)
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 van Hazel GA, Heinemann V, Sharma NK. et al. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 2016; 34 (15) 1723-1731 DOI: 10.1200/JCO.2015.66.1181. (PMID: 26903575)
    CrossrefPubMedGoogle Scholar
  • 31 Hendlisz A, van den Eynde M, Peeters M. et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28 (23) 3687-3694 DOI: 10.1200/JCO.2010.28.5643. (PMID: 20567019)
    CrossrefPubMedGoogle Scholar
  • 32 van Hazel G, Blackwell A, Anderson J. et al. Randomised phase 2 trial of SIR-spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004; 88 (02) 78-85 DOI: 10.1002/jso.20141. (PMID: 15499601)
    CrossrefPubMedGoogle Scholar
  • 33 Palmer DH, Hawkins NS, Vilgrain V. et al. Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study. Future Oncol 2020; 16 (01) 4315-4325 DOI: 10.2217/fon-2019-0658. (PMID: 31797680)
    CrossrefPubMedGoogle Scholar